In Depth

Featured article

Digital twins become the new battleground for CDMOs

Also in this section

How physical AI is rewiring pharma manufacturing

UAE's CellSave Arabia targets growth in regenerative medicine

Drugmakers fortify supply chains ahead of obesity pill boom

China’s biotech surge upends the global CDMO model

Gilead doubles down on cell therapy: inside the $7.8bn Arcellx acquisition

Autologous vs allogeneic: cell therapy development's oncology shift

2025 dominated in ALS research

Merck’s strategic shift following $6.7bn Terns acquisition